Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Grade II Neuroendocrine Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05746208
What this trial is testing

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
University of California, San Francisco 29
Early research (Phase 1)Study completedNCT00019019
What this trial is testing

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerKidney Cancer+6 more
National Institutes of Health Clinical Center (CC) 70
Not applicableLooking for participantsNCT04464122
What this trial is testing

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmNeuroendocrine Tumor Grade 1+2 more
University of Roma La Sapienza 60
Testing effectiveness (Phase 2)Study completedNCT00027638
What this trial is testing

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Who this might be right for
Gastrointestinal Carcinoid TumorIslet Cell TumorLung Cancer+1 more
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00113360
What this trial is testing

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine CarcinomaIslet Cell Carcinoma
M.D. Anderson Cancer Center 67
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Testing effectiveness (Phase 2)WithdrawnNCT00227773
What this trial is testing

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Who this might be right for
Gastrointestinal Carcinoid TumorIslet Cell Carcinoma
Eastern Cooperative Oncology Group
Not applicableStudy completedNCT00899496
What this trial is testing

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Who this might be right for
Cancer
Wake Forest University Health Sciences 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT03333616
What this trial is testing

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Who this might be right for
Genitourinary CancerAdrenocortical CarcinomaNon-urothelial Bladder+5 more
Dana-Farber Cancer Institute 100
Testing effectiveness (Phase 2)Looking for participantsNCT07115043
What this trial is testing

Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+6 more
AstraZeneca 120
Testing effectiveness (Phase 2)Looking for participantsNCT06472388
What this trial is testing

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsProgressionNeuroendocrine Tumor Grade 1+4 more
AC Camargo Cancer Center 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284774
What this trial is testing

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Who this might be right for
Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Study completedNCT00193531
What this trial is testing

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Who this might be right for
Neuroendocrine Carcinoma
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Ended earlyNCT04042714
What this trial is testing

TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

Who this might be right for
High-grade Extra Pulmonary Neuroendocrine Cancer
Baylor Research Institute 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT04802174
What this trial is testing

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

Who this might be right for
SCLCSmall Cell CancerAdvanced Solid Tumor+1 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Study completedNCT00004922
What this trial is testing

Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Carcinoma of Unknown PrimaryNeuroendocrine CarcinomaNeuroendocrine Carcinoma of the Skin
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Testing effectiveness (Phase 2)Study completedNCT00445965
What this trial is testing

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Who this might be right for
Brain and Central Nervous System TumorsIntraocular MelanomaLung Cancer+7 more
Memorial Sloan Kettering Cancer Center 78
Testing effectiveness (Phase 2)UnknownNCT00637637
What this trial is testing

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Who this might be right for
Cancer
Oncology Institute of Southern Switzerland 60
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Next Page
40